Serum interleukin-6, tumour necrosis factor-a, D-dimer after recombinant human brain natriuretic peptide combined with levosimendan in patients with heart failure

Background: This study evaluates the impact of recombinant human brain natriuretic peptide (Rh-BNP) combined with levosimendan on therapeutic efficacy, inflammatory markers, and nutritional status in patients with heart failure (HF). Methods: A total of 162 heart failure patients treated between March 2022 and March 2024 were randomly assigned to three treatment groups: Group 1 received conventional therapy plus Rh-BNP Group 2 received conventional therapy plus levosimendan, and Group 3 received a combination of both Rh-BNP and levosimendan, along with nutritional support. Efficacy was assessed regarding cardiac function, renal function, inflammatory biomarkers (IL-6, TNF-a), nutritional status, and quality of life. Results: All three treatment groups improved cardiac and renal function, reduced inflammatory markers, and enhanced nutritional status. However, the combination therapy group (Group 3) demonstrated the most significant improvements across all parameters, including a greater reduction in IL-6 and TNF-a levels and an improvement in the Mini Nutritional Assessment (MNA) score. Additionally, the combination treatment led to marked improvements in quality of life and reduced symptoms of depression and anxiety compared to the other groups (P< 0.05). Conclusions: Rh-BNP combined with levosimendan, alongside nutritional support, offers significant benefits in treating heart failure, enhancing cardiac function, reducing inflammation, improving nutritional status, and improving the overall quality of life for patients.